Kodiak Sciences announces emerging durability data from Phase 1 study of KSI-301
Kodiak Sciences announced emerging durability data in patients with wet age-related macular degeneration treated in its Phase 1b clinical study of its investigational therapy KSI-301. "The emerging durability data presented suggest our objective for KSI-301 to be a leading next-generation anti-VEGF therapy with a long-interval durability profile is achievable," said Jason Ehrlich, Kodiak's Chief Medical Officer and Chief Development Officer. "In the presented cohort of treatment-naive wet AMD patients followed for twelve weeks or longer after the loading phase, all achieved a treatment-free interval of three months or longer, with the majority reaching a four- or five-month interval and continuing to be followed without retreatment to date. While early, these durability and efficacy data, together with the continued promising safety data in over 250 injections and 100 patients, support our wet AMD 'DAZZLE' pivotal study design evaluating every three-, four- and five-month dosing with KSI-301."